鹭燕医药(002788) - 2018 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2018 was ¥2,599,969,607.65, representing a 60.33% increase compared to ¥1,621,661,503.69 in the same period last year[8] - Net profit attributable to shareholders was ¥32,379,175.19, up 39.52% from ¥23,207,455.33 year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥32,226,007.98, reflecting a 42.53% increase from ¥22,610,167.46 in the previous year[8] - The basic earnings per share increased to ¥0.25, a rise of 38.89% compared to ¥0.18 in the same period last year[8] - Operating revenue increased by 60.33% year-on-year, attributed to the company's leading position in the joint price limit procurement of pharmaceuticals in Fujian Province and the impact of acquisitions in 2017[15] - Net profit attributable to shareholders increased by 39.52% year-on-year, driven by the same factors as operating revenue[15] - The net profit excluding non-recurring gains and losses grew by 42.53% year-on-year, reflecting the ongoing benefits from the procurement results and acquisitions[16] - Basic and diluted earnings per share increased by 38.89% year-on-year, reflecting the growth in net profit[19] Assets and Shareholder Information - The total assets at the end of the reporting period were ¥5,576,793,651.37, an increase of 8.66% from ¥5,132,422,708.63 at the end of the previous year[8] - The net assets attributable to shareholders were ¥1,505,167,300.61, which is a 2.13% increase from ¥1,473,719,309.80 at the end of the previous year[8] - The company reported a total of 24,315 common shareholders at the end of the reporting period[11] - The largest shareholder, Xiamen Maidi Ken Technology Co., Ltd., held 35.21% of the shares, amounting to 45,125,000 shares, with 7,770,000 shares pledged[11] Cash Flow and Operating Activities - The net cash flow from operating activities was negative at -¥538,596,759.64, worsening by 236.04% compared to -¥160,279,665.96 in the same period last year[8] - Cash flow from operating activities decreased by 236.04% year-on-year, mainly due to increased cash outflows from expanded operations and prepayment methods used by newly acquired companies[17] - The company's cash and cash equivalents at the end of the period were ¥326.87 million, a decrease of 39.67% compared to the beginning of the period, primarily due to increased business payments resulting from year-on-year growth[15] Costs and Investments - Operating costs rose by 60.36% year-on-year, primarily due to business growth[16] - Investment cash outflows increased by 100% year-on-year, primarily due to acquisition expansions[17] Future Projections and Acquisitions - The company plans to achieve a net profit attributable to shareholders in the range of ¥69.80 million to ¥82.49 million for the first half of 2018, representing a year-on-year increase of 10% to 30%[24] - The company completed the acquisition of 49% equity in Sichuan Luyan Shibo Pharmaceutical Co., Ltd., resulting in 100% ownership, to support strategic expansion in Sichuan Province[20]